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Abstract
Background: Epidemiologic knowledge regarding noncardiovascular and all-cause
mortality in apparently healthy cats (AH) and cats with preclinical hypertrophic car-
diomyopathy (pHCM) is limited, hindering development of evidence-based
healthcare guidelines.
Objectives: To characterize/compare incidence rates, risk, and survival associated
with noncardiovascular and all-cause mortality in AH and pHCM cats.
Animals: A total of 1730 client-owned cats (722 AH, 1008 pHCM) from
21 countries.
Methods: Retrospective, multicenter, longitudinal, cohort study. Long-term health
data were extracted by medical record review and owner/referring veterinarian
interviews.
Results: Noncardiovascular death occurred in 534 (30.9%) of 1730 cats observed
up to 15.2 years. Proportion of noncardiovascular death did not differ significantly
between cats that at study enrollment were AH or had pHCM (P = .48). Cancer,
chronic kidney disease, and conditions characterized by chronic weight-loss-
vomiting-diarrhea-anorexia were the most frequently recorded noncardiovascular
causes of death. Incidence rates/risk of noncardiac death increased with age in AH
and pHCM. All-cause death proportions were greater in pHCM than AH (65% ver-
sus 40%, respectively; P < .001) because of higher cardiovascular mortality in
pHCM cats. Comparing AH with pHCM, median survival (study entry to non-
cardiovascular death) did not differ (AH, 9.8 years; pHCM, 8.6 years; P = .10), but
all-cause survival was significantly shorter in pHCM (P = .0001).
Conclusions and Clinical Importance: All-cause mortality was significantly greater
in pHCM cats due to disease burden contributed by increased cardiovascular death
superimposed upon noncardiovascular death.
K E YWORD S
cancer, chronic kidney disease, epidemiology, mortality, survival
1 | INTRODUCTION
Contemporary pet ownership surveys demonstrate substantial growth in
feline pet populations. In the United States, there were approximately
74 million pet cats in 2012 (AVMA, US Pet Ownership & Demographics
Sourcebook, 2012), and 94.2 million estimated for the 2017-2018
time period (2017-2018 APPA National Pet Owners Survey, http://
americanpetproducts.org/pubs_survey.asp). Nevertheless, little has been
published about long-term health outcomes of domestic cats, con-
straining development of effective health-monitoring strategies.
Most studies derive from veterinary insurance reports,1-5 ceme-
tery6 and necropsy records,7 surveys,8-10 clinical registries,11 national
research databases,12 health screening, and 13 medical record reviews
from primary14,15 and tertiary care16 practices. Information from these
sources is generally limited to prevalence data, that is, the percentage
of deaths due to a disease or condition identified at a point in time.
However, insights regarding incidence, that is, the rate of new condi-
tions arising in populations over time, are scarce; risk and survival com-
parisons for preclinical cohorts are largely unreported; and population
effects related to age and cause-specific mortality remain uncertain.
The REVEAL study reported cardiovascular morbidity and survival
in 1730 apparently healthy cats (AH) and cats with preclinical hyper-
trophic cardiomyopathy (pHCM).17 To further our understanding of
feline longevity, the present study aimed to identify the epidemiology
of noncardiovascular and all-cause death and assess its overall impact
on health in the same population. Specific objectives were to deter-
mine from medical records, the major causes of death, contrast inci-
dence rates, risk, and survival characteristics, and compare these
observations between susceptible populations and age groups over a
prolonged period of time.
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2 | MATERIALS AND METHODS
2.1 | Study design
Data were derived from an analysis of medical and demographic data
collected for the REVEAL Study17 project. Ethical review committee
approval was obtained where required.
2.2 | Cats
Analysis included 1730 cats: 722 AH and 1008 pHCM (430 non-
obstructive hypertrophic cardiomyopathy [HCM] and 578 obstructive
hypertrophic cardiomyopathy [HOCM]).17 Enrolled cats had normal
physical examination except for the presence of heart murmurs in
some cats. No other known serious illness or medical history abnor-
malities were detected. All had echocardiographic examinations per-
formed at the time of study entry. The study cohort of AH received
echocardiographic examinations for preanesthetic workups, to evalu-
ate cardiac status when heart murmurs were detected, as part of case
recruitment of AH without significant heart disease for the present
study, and for breed screening in certain pedigrees.
2.2.1 | Inclusion criteria
Each investigator had a searchable echocardiographic andmedical record
database permitting detailed review and long-term health follow-up.
Medical records were examined for cats diagnosed with either HCM or
HOCM, and AHwithout cardiomyopathy, whose health outcomes could
be ascertained for at least 5 years after the date of study entry. Archived
echocardiographic images were reviewed to confirm diagnosis. Study
entry was recorded as the date when echocardiographic examination
was first performed.17
2.2.2 | Exclusion criteria
Any of the following conditions diagnosed at or before study entry resulted
in study exclusion: congestive heart failure; arterial thromboembolism; syn-
cope; heartworm disease; arterial hypertension (systolic arterial blood pres-
sure ≥180 mmHg); hyperthyroidism; anemia; chronic kidney disease (CKD),
defined as any combination of serum creatinine concentration above labora-
tory reference interval, urine concentrating ability deemed to be inadequate
or isosthenuria, proteinuria, and small, irregular kidneys; cardiomyopathy
other than pHCM; congenital heart disease; cancer; any systemic, endocrine,
hepatobiliary, pancreatic, or chronic gastrointestinal disease; and medical or
surgical condition judged capable of limiting life expectancy.
2.3 | Study sites
Investigators participated from 50 veterinary centers in 21 countries.17
2.4 | Echocardiography
Cardiac diagnoses were confirmed from archived echocardiograms.
Left ventricular (LV) hypertrophy represented end-diastolic LV free
wall and or interventricular wall thickness ≥6 mm.18 Hypertrophic
obstructive cardiomyopathy was defined as LV hypertrophy with sys-
tolic anterior motion of the mitral valve, diffuse LV outflow tract tur-
bulence, and peak systolic outflow velocity ≥2.5 m/s, whereas HCM
represented hypertrophic cardiomyopathy without LV outflow tract
obstruction.
2.5 | Data collection and outcomes assessment
Medical records where the first echocardiographic examination was per-
formed between November 2001 and January 2011 were reviewed to
TABLE 1 Recorded deaths in cats that at study entry were diagnosed as apparently healthy or with preclinical HCM/HOCM
Apparently healthy cats HCM HOCM HCM/HOCM
n = 722 n = 430 n = 578 n = 1008
Cause of death Number of events (%) Number of events (%) Number of events (%) Number of events (%)
Cause-specific mortality
Cancer 105 (14.5) 52 (12.1) 51 (8.8) 103 (10.2)
Chronic kidney disease 46 (6.4) 41 (9.5) 35 (6.1) 76 (7.5)
Chronic weight loss-vomiting-
diarrhea-anorexia
32 (4.4) 24 (5.6) 26 (4.5) 50 (5.0)
Other diseases* 47 (6.5) 42 (9.8) 33 (5.7) 75 (7.4)
Unknown causes 49 (6.8) 25 (5.8) 43 (7.4) 68 (6.7)
Overall mortality
Noncardiovascular causes 230 (31.9) 159 (37.0) 145 (25.1) 304 (30.2)
Cardiovascular causes 7 (1.0) 115 (26.7) 166 (28.7) 281 (27.9)
All causes** 286 (39.6) 299 (69.5) 354 (61.2) 653 (64.8)
Note: Data are arranged by the cause of death.
Abbreviations: HCM, nonobstructive hypertrophic cardiomyopathy; HOCM, obstructive hypertrophic cardiomyopathy.
*Death related to anesthesia, respiratory diseases, central nervous system diseases, hepatobiliary diseases, toxicoses, endocrine diseases, trauma.
**Includes all cardiovascular, noncardiovascular, and unknown causes of death.
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identify recorded death or permitted at least 5 years of follow-up. Data
collection extended to January 2016. Pertinent demographic and sur-
vival information was recorded. Serum thyroxine and creatinine concen-
trations and systolic arterial blood pressure results closest to the date ofT
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F IGURE 1 Comparison of cardiovascular, noncardiovascular, and all-
causemortality rates per 1000 cat-years recorded over the study duration
for 1730 cats. Clinical statuswas designated at study entry for
722 apparently healthy cats or preclinical hypertrophic (HCM) and
hypertrophic obstructive (HOCM) cardiomyopathy (HCM/HOCM,
n =1008)
F IGURE 2 Mortality rates per 1000 cat-years for noncardiovascular
(upper graph) and all-cause (lower graph) death compared by age quartile
(Q) at the time of study entrywhen cats were diagnosed as apparently
healthy cats (AH, n = 722) or preclinical hypertrophic (HCM) and
hypertrophic obstructive (HOCM) cardiomyopathy (n = 1008)
F IGURE 3 Risk of noncardiovascular death recorded at 1, 2.5,
5, 7.5, and 10-year intervals after study entry in 1730 cats which, at
the time of study entry, were diagnosed as apparently healthy cats
(AH, n = 722) or preclinical hypertrophic (HCM) and hypertrophic
obstructive (HOCM) cardiomyopathy (HCM/HOCM, n = 1008)
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diagnosis were examined but were not available for every case. Date of
death was designated by natural death or euthanasia. Cause of death
was inferred to be the predominant condition or disease which, based on
all available information including medical history and physical examina-
tion findings, diagnostic imaging, clinical pathology, ancillary testing,
histopathology from biopsy, and or necropsy, contributed most substan-
tially. When cause or date of death was unavailable, or if medical and
clinical circumstances associated with death were uncertain, referral
veterinarians or the pet owners were interviewed, aided by a standard-
ized medical questionnaire.17 Cause of death was grouped into catego-
ries. Cancer death was supported by detection of a mass, masses,
lymphadenopathy by physical examination or diagnostic imaging, or
by confirmation from cytology, histology, or necropsy when performed.
Supporting CKD death were history of polyuria and polydipsia,
serum creatinine concentration exceeding laboratory reference interval,
isosthenuria or inadequate urine concentrating ability, proteinuria, and
small and irregular kidney size and shape by physical examination or
abdominal ultrasound. Death was attributed to debilitation caused by
1 or more of the following: chronic weight loss, vomiting, diarrhea, and or
anorexia (CWLVDA). Etiologies for CWLVDA mortality included exo-
crine pancreatic insufficiency and chronic, non-neoplastic gastrointesti-
nal disease including inflammatory bowel disease, and without clinical
evidence for cancer, endocrine, metabolic diseases, or known conditions
that could have caused these signs. Cancer or CKD death was the
designated cause of death if criteria for these diagnoses were met, even
when malaise, weight loss, vomiting, or diarrhea was present. A non-
cardiovascular death category denoted as “other causes”was designated
when death resulted from anesthetic complications, trauma, endocrine
diseases including diabetes mellitus and hyperthyroidism, hepatobiliary
diseases including hepatic lipidosis and cholangiohepatitis, central ner-
vous system diseases, toxicoses, and respiratory system diseases. Death
was classified as “unknown cause” when there was insufficient or con-
flicting information or overlapping comorbidities.
2.6 | Statistical analysis
Date of study entry was the time of echocardiographic examination and
diagnosis. Data obtained at this time were evaluated in descriptive, base-
line analyses, reported as mean and standard deviation for normally
distributed variables, and median (interquartile range) for nonnormally
distributed variables. Analysis of variance was used for between-group
analyses, as error residuals were normally distributed based on visual
inspection. Analyses for proportions of categorical variables were evalu-
ated using chi-square or Fisher's exact test as appropriate. A generalized
linear model was used to calculate incidence for the entire population and
cohort level by age quartile expressed as rates per 1000 cat-years, as
goodness of fit assumptions were met. Kaplan-Meier analysis was used
to calculate proportion at-risk and compare noncardiovascular and all-
cause survival within AH and HCM/HOCM cohorts. Survival time was
further assessed at 1, 2.5, 5, 7.5, and 10-year intervals after study entry,
and these specified time points dictated the percentage of patients at-risk
as calculated by Kaplan-Meier, permitting a cross-sectional view of the
respective time points. Additional analyses included stratification at age
quartile determined by age at study entry. Univariate time-to-event sur-
vival analyses were performed using Kaplan-Meier product limit esti-
mates, where survival range was presented if median survival was not
reached. Statistical differences between strata were determined by a log-
rank test. Time-to-event survival time analyses represented time from
study entry to end-date (death, date lost to follow-up, or remaining alive
at study termination). Cases lost to follow-up or remaining alive were
right-censored. Analyses were performed with SAS 9.4 (Cary, North
Carolina). P < .05was deemed significant.
3 | RESULTS
3.1 | Population characteristics at time of diagnosis
Study population demographic data were recently reported.17 Briefly,
median age of AH (4.9 years) was significantly younger than HCM
(7.4 years; P < .001) and HOCM (5.7 years; P = .01) cohorts; HOCM were
younger thanHCM(P< .001) cohorts, andAHwere also younger compared
with theHCM/HOCMcohort (6.5 years; P< .001). Thirty-four breeds com-
prised the total population. Domestic Shorthair, Maine Coon cat, Persian,
Domestic Longhair, andNorwegian Forest cat breedsweremost prevalent.
3.2 | Overall mortality
Noncardiovascular death was recorded in 534 (30.9%) of 1730 cats.
These comprised 230 (31.9%) of 722 AH, and 304 (30.2%) of 1008
HCM/HOCM (159 [37.0%] of 430 HCM and 145 [25.1%] of
578 HOCM; Table 1). Comparing AH with HCM/HOCM cats, there was
no significant difference between the proportion of noncardiovascular
F IGURE 4 Survival analysis of 1730 cats that at study entry were
diagnosed as apparently healthy (n = 722) or with preclinical
HCM/HOCM (n = 1008). Percentage of cats that have not
experienced death (y-axis) is plotted against time from study entry to
time of noncardiovascular death (x-axis). Survival statistics include
median and range (smallest and largest value): Apparently healthy
cats, 9.8 years, 6 days-14.1 years; HCM/HOCM cats, 8.6 years,
2 days-15.2 years (P = .10). HCM, nonobstructive hypertrophic
cardiomyopathy; HOCM, obstructive hypertrophic cardiomyopathy
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mortality (P = .48). Cancer, CKD, and CWLVDAwere themost commonly
recorded causes of noncardiovascular death. Demographic characteristics
were compared for cardiovascular and noncardiovascular mortalities
(Tables 1 and2). Approximatemale:female ratio for AH andHCM/HOCM
cohorts were for cancer, 1:1, 1.8:1; CKD, 0.6:1, 2.5:1; and CWLVDA,
1.5:1, 2.6:1, respectively).
3.2.1 | Incidence
Mortality rates per 1000 cat-years were compared between cohorts
defined by age quartile at the time of study entry and arranged by cause of
death (Table 3). Noncardiovascular mortality was similar between AH and
HCM/HOCM cats; however, all-cause mortality was substantially higher in
HCM/HOCM compared to AH due to cardiovascular death, which
occurred frequently in HCM/HOCM cats but rarely in AH (Figure 1). Over-
all, noncardiovascular and all-cause mortality rates were lowest in the first
2 age quartiles and increased with age (Table 3, Figure 2). Specifically, inci-
dence rates for noncardiovascular death in AH were slightly more than
twice higher in both the second compared with the first age quartile and in
the third compared with the second quartile, and 2.4 times higher in the
fourth compared with the third age quartile; in HCM/HOCM cats, non-
cardiovascular mortality was 2 times higher in the second compared with
the first quartile, 1.8 times higher in the third compared with the second
quartile, and 2.6 times higher in the fourth comparedwith the third quartile.
For cause-specificmortality rates inAH, cancer deathwas 23.3 times higher
in cats >10 years than in cats <2.5 years old; CKD death was 51 times
higher in cats>10 than for cats<2.5 years; andCWLVDAdeathwas3 times
higher in cats >10 than <2.5 years. In HCM/HOCM cats, cancer, CKD, and
CWLVDA death rates also increased with age. Comparing their mortality
rates between cats older than 10 years with cats younger than 2.5 years,
cancer death was 6.3 times higher, CKD death was 27.2 times higher, and
CWLVDA death was 14.3 times higher, respectively. In both AH and
HCM/HOCM cohorts, CKD death incidence rate increased substantially
with age, especially in the third and fourth age quartiles (Table 3).
3.2.2 | Risk
Risk of death due to noncardiovascular and all-cause mortalities
increased variably at 1, 2.5, 5, 7.5, and 10-year intervals following
F IGURE 5 Survival analysis of 1730 cats that at study entry were
diagnosed as apparently healthy (n = 722) or with preclinical
HCM/HOCM (n = 1008). Percentage of cats that have not
experienced death (y-axis) is plotted against time from study entry to
time to all-cause death (x-axis). Survival statistics include median and
range (smallest and largest value): Apparently healthy cats, 8.3 years,
6 days-14.1 years; HCM/HOCM cats, 5.1 years, 2 days-15.2 years
(P = .0001). HCM, nonobstructive hypertrophic cardiomyopathy;
HOCM, obstructive hypertrophic cardiomyopathy
F IGURE 6 Survival analysis of 1730 cats stratified by age quartile
(Q) at study entry when diagnosed as apparently healthy (n = 722; A)
or with preclinical HCM/HOCM (n = 1008; B), and that died over time
from noncardiovascular causes. Percentage of cats that have not
experienced death (y-axis) is plotted against time from study entry to
time to noncardiovascular death (x-axis). A, Q1: median not achieved,
range 46 days-14.1 years; Q2; median 8.6 years, range 15 days-
11.0 years; Q3: median 7.3 years, interquartile range (IQR)
3.8-13.6 years; Q4: median 3.4 years, IQR 2.2-6.9 years. Pairwise
comparisons between age quartiles were P < .0001, except Q1 versus
Q2 (P = .0009) and Q2 versus Q3 (P = .0007). B, All median, IQR. Q1:
9.8 years, 9.0-13.1 years; Q2: 11.1 years, 7.5-12.5 years; Q3:
8.0 years, 5.1-8.8 years; Q4: 4.2 years, 2.2-6.3 years. Pairwise
comparisons between age quartiles were P < .0001, except Q1 versus
Q2 (P = .006). HCM, nonobstructive hypertrophic cardiomyopathy;
HOCM, obstructive hypertrophic cardiomyopathy
10 FOX ET AL.
study entry (Table 4, Figure 3). For noncardiovascular mortality, the
largest risk increments were recorded at 2.5 years compared with
1 year, and 5 years compared with 2.5 years following study entry
(in AH 2.4 and 1.8 times higher, respectively; in HCM/HOCM cats 1.9
and 2.1 times higher, respectively). For all-cause mortality, the largest
risk increments were recorded at 2.5 years compared with 1 year and
at 5 years compared with 2.5 years (in AH 2.7 and 1.9 times higher,
respectively; in HCM/HOCM 2.0 and 1.9 times higher at each com-
parison, respectively). Noncardiovascular risk was 4.3 and 3.9 times
higher at 5 years compared with 1 year following study entry for AH
and HCM/HOCM cats, respectively. In AH, risk of cancer, CKD, and
CWLVDA death was 3.9, 7.3, and 4.7 times higher at 5 years com-
pared with 1 year following study entry, respectively; risks for the
F IGURE 7 Survival analysis of 1730 cats stratified by age quartile
(Q) at study entry when diagnosed as apparently healthy (n = 722; A)
or with preclinical HCM/HOCM (n = 1008; B), and that died over time
from all-cause death. Percentage of cats that have not experienced
death (y-axis) is plotted against time from study entry to time to all-
cause death (x-axis). A, Q1: Median not achieved, range 46 days-
14.1 years; Q2: median 8.6 years, range 15 days-11.0 years; Q3:
median 6.9 years, interquartile range (IQR) 3.3-13.6 years; Q4: median
3.1 years, IQR 2.0-5.5 years. Pairwise comparisons between age
quartiles were P < .0001, except Q1 versus Q2 (P = .002). B, All
median, IQR. Q1: 7.5 years, 4.1-9.8 years; Q2: 6.5 years,
3.1-11.1 years; Q3: 5.0 years, 2.7-8.0 years; Q4: 3.0 years,
1.3-5.2 years. Pairwise comparisons between age quartiles were
P < 0001, except Q1 versus Q2 (P = .10) and Q2 versus Q3
(P = .0003). HCM, nonobstructive hypertrophic cardiomyopathy;
HOCM, obstructive hypertrophic cardiomyopathy
F IGURE 8 Survival analysis of 1730 cats that at study entry were
diagnosed as apparently healthy (n = 722) or preclinical HCM/HOCM
(n = 1008), and that died over time due to cancer, CKD, or CWLVDA.
Percentage of cats that have not experienced death (y-axis) is plotted
against time from study entry to time to cause-specific death (x-axis).
Survival statistics include range (smallest and largest value); median
survival was not achieved. A, Death from cancer. AH, 6 days-
14.1 years; HCM/HOCM cats, 14 days-13.1 years (P = .28). B, Death
from CKD. AH, 28 days-14.1 years; HCM/HOCM cats, 16 days-
13.1 years (P = .04). C, Death from CWLVDA. AH 6 days-14.1 years;
HCM/HOCM cats, 2 days-15.2 years (P = .18). HCM, nonobstructive
hypertrophic cardiomyopathy; HOCM, obstructive hypertrophic
cardiomyopathy; CKD, chronic kidney disease; CWLVDA, chronic
weight-loss-vomiting-diarrhea-anorexia
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same mortalities in HCM/HOCM cats were 3.5, 7.0, and 4.9 times
higher at 5 years compared with 1 year after study entry, respectively.
The increment of risk for these mortalities was comparatively higher
at 5 years compared with 10 years after study entry for AH and
HCM/HOCM cats. Comparative risk of CKD death was greatest in
cats that were in the fourth age quartile at study entry (Table 4).
3.3 | Survival analyses
Survival time from study entry to noncardiovascular death did not
differ significantly in AH (median, 9.8 years; range, 6 days-14.1 years)
compared with HCM/HOCM cats (median, 8.6 years; range, 2 days-
15.2 years; P = .10; Figure 4). Survival times to all-cause death were
significantly shorter in HCM/HOCM cats (median, 5.1 years; range,
2 days-15.2 years) compared to AH (median, 8.3 years; range, 6 days-
14.1 years; P = .0001; Figure 5). Survival curves for AH andHCM/HOCM
cats stratified by age quartile at time of study entry divergedmarkedly for
noncardiovascular (Figure 6) and all-cause (Figure 7) death, most notably
for the second and third, and the third and fourth age quartiles. This was
largely caused by cancer and CKD deaths (Table 4). For example, at
2.5 years after study entry, risk of cancer death in AH was 7.1% in the
third and 17.7% in the fourth age quartile. At 7.5 years after study entry,
risk of cancer death was 16.7% in the third and 36.7% in the fourth age
quartile.
Survival from study entry to recorded cancer death did not differ
significantly between AH (median not achieved [NA]; range, 6 days-
14.1 years) and HCM/HOCM cats (NA; range, 14 days-13.1 years;
P = .28; Figure 8A). By contrast, survival to CKD death was significantly
shorter in HCM/HOCM cats (NA; range, 16 days-13.1 years) compared
with AH (median NA; 28 days-14.1 years; P = .04; Figure 8B). Survival to
CWLVDA death did not differ significantly between AH (NA; range,
6 days-14.1 years) compared with HCM/HOCM cats (median NA, range,
2 days-15.2 years; P = .18; Figure 8C).
4 | DISCUSSION
We identified noncardiovascular causes of death and examined all-cause
mortality, incidence rates, risk, and survival characteristics in 1730 cats.
To the best of our knowledge, this represents the first long-term compari-
son of causes of death between populations that at study entry were ini-
tially healthy or had preclinical HCM/HOCM. Death from cancer, CKD
and CWLVDA represented 75%-80% of noncardiovascular mortality in
cats originating from around the world, confirming the major impact of
these conditions on life expectancy.1-6,8,11-13 These findings complement
the epidemiology of cardiovascular mortality reported from the same
population.17 In the present study, all-cause mortality was significantly
greater and survival duration was significantly shorter in HCM/HOCM
cats compared to AH, due to cardiovascular death that was substantial in
HCM/HOCMcats but rare inAH.
Cancer was themost frequently recorded cause of noncardiovascular
death. Apparently healthy cats and HCM/HOCM cats with cancer death
did not differ significantly for age at study entry or for survival time. In AH
compared with HCM/HOCM cats, the increment of cancer death risk
was substantial by 5 years (1 in 9 and 1 in 14, respectively) comparedwith
1 year (1 in 36 and 1 in 50, respectively) after study entry. By comparison
at 10 years after study entry, risk was 1 in 7 and 1 in 10, respectively.
Population-based data describing epidemiology of feline neoplasia are
scant. Direct comparison with our findings is problematic due to diverse
study populations, disparate inclusion criteria, and dissimilar methods for
disease estimation.19-23 Lymphoma is themost commonly reported feline
neoplasm20 and most prevalent form of gastrointestinal cancer.24,25
However, we did not attempt to document histological diagnoses in all
catswhose deathswere attributed to cancer in our study.
Chronic kidney disease was the second most commonly recorded
cause of noncardiovascular death. As with cancer, CKD death predomi-
nantly affected middle-aged and older cats. Similar to cancer, in both AH
and HCM/HOCM cats, the increment of CKD death risk was greatest at
5 years (1 in 23 and 1 in 20, respectfully) compared with 1 year (1 in
167 and 1 in 143, respectively) after study entry. By comparison, CKD
death risk was 1 in 15 and 1 in 13 at 10 years, after study entry, respec-
tively. Neutered male compared with spayed female status was reported
to be a CKD risk factor.26 In our study, sex ratio with CKD death was
approximately 1.6 to 1 female-to-male in AH and 2.5 to 1male-to-female
in HCM/HOCM cats. However, heart disease was excluded in AH,
whereas HCM/HOCM is associated with strong male predilection, possi-
bly explaining these differences.
Survival from study entry to CKD death was significantly shorter
in HCM/HOCM cats compared with AH. Although age at study entry
did not differ significantly between AH and HCM/HOCM cats with
recorded CKD death, the HCM/HOCM cohort was significantly older
than AH and might have introduced a population bias, because preva-
lence of CKD increases with age.13,26-29 Consequently, we cannot
resolve whether pHCM predisposed to acute kidney injury as a
hypothesis for their shorter survival time to CKD death, compared
with AH. This merits further study.
Death associated with CWLVDA was the third most commonly
recorded cause of noncardiovascular death. Compared with cancer
death, incidence rates were approximately one-third lower in AH and
one-half lower in HCM/HOCM cats, respectively. Consistent with
cancer and CKD death, the increment of risk for CWLVDA death in
AH and HCM/HOCM cats was greatest at 5 years (approximately 1 in
30 and 1 in 29 respectively) compared with 1 year (1 in 143) after
study entry. Middle-age predilection has been reported for feline
inflammatory bowel disease, 1 of the most common feline enteropa-
thies.30,31 In our study, the cohort of AH with recorded CWLVDA
death were middle-aged at the time of study entry.
How best to apply epidemiology to promote disease detection and
improve feline health remains a long-standing topic of interest,13,28,32-37
especially because current metrics to assess disease have limitations. Age
categories are considerably subjective, as designated, for example, by
middle-aged, adult, mature, senior, or geriatric labels that are commonly
applied. Indeed, interpreting age-appropriate physical and physiologic
aging changes may be ambiguous. Collectively, predicting risk based
solely upon time from birth is indeterminate.38-41 Nonetheless, increased
health screening has been routinely advocated for “older” cats,
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emphasizingmedical history, physical examination, and laboratory testing
as footings to detect illness.28,32-36,42 Often, however, medical history
and physical examination findings are vague or unremarkable. Further-
more, blood test variables might be unaffected, particularly in early dis-
ease stages and even when certain disease has progressed.43 Laboratory
reference intervals that reflect normal aging improves test acuity,15 but
available data are limited. Thus, screening clinical pathology test values
frequently fall within normal reference intervals,13 and normal findings
might not reflect the state of health nor assure the absence of disease.
The present study reports survival characteristics, incidence
rates, and mortality risk in feline populations that at study entry were
apparently healthy or had pHCM. These methods afford a constructive
approach to support healthcare planning, and our findings provide infor-
mative considerations for future screening programs.We prioritized anal-
ysis of incidence over prevalence in order to compare noncardiovascular,
all-cause, and cause-specific mortality across age quartiles and between-
study populations. Most feline reports emphasize prevalence,1-13 which
describes the total number of cases in a study population at a single time
point, but is affected by disease duration and occurrence, and is not well
suited for monitoring disease trends.44 Our study revealed that cancer,
CKD, and CWLVDA death were the major causes of noncardiovascular
death. Although older cats had the highest noncardiovascular mortality
event rates, substantial mortality was also recorded in the middle 2 age
quartiles, ages not customarily targeted for enhanced wellness screening.
We also observed that the greatest increment of risk for death caused by
cancer, CKD, and CWLVDA occurred at 2.5 and 5 years compared with
1 year after study entry. The increment of risk for noncardiovascular
death after study entry in AH and HCM/HOCM cats increased approxi-
mately 2.4 and 1.9 times at 2.5 years compared with 1 year, respectively,
and increased further, by approximately 1.8 and 2.1 times at 5 years com-
pared with 2.5 years after study entry, respectively. These findings might
contribute to planning screening visits.
There were several important study limitations. As this was a retro-
spective study, it was not feasible to collect comprehensive test data,
biopsy procedures, or necropsy results on every case, and we were not
able to refine survival analyses according to histologic grading of cancer.
Although exclusionary criteria were imposed to screen out cases with
obvious clinical illness, some diseases may have been undetected. Attrib-
uting cause of death in cases associated with gastrointestinal signs of dis-
ease can be difficult. Indeed, well-recognized challenges have been
reported, including shifting and controversial classification systems,
evolving terminology, unsettled diagnostic criteria, and uncertain test
accuracy.30 Distinguishing between inflammatory bowel disease and lym-
phoma, the 2 principal diseases affecting the feline gastrointestinal sys-
tem is especially problematic and comorbidities may exist.45-52 Although
cause of death was relegated to an “unknown category”whenever infor-
mationwas insufficient, misclassification of cause-specific deathwas pos-
sible. However, the broader categories of noncardiovascular and all-
cause death still providemeaningful bases for comparing populations and
age quartiles. Referral bias might have been present at some study sites.
Moreover, some selection bias might have resulted because some AH
were examined with echocardiography to assess a heart murmur for
breeding examination or preanesthesia evaluation. It was not possible to
assure that study populations represented endemic disease burdens in
each geographic region. Thus, incidence ratesmight have been overrepre-
sented or underrepresented at some sites. However, we are unaware of
comprehensive survey data confirming geographic distribution of feline
diseases. Our relatively large study population originating from varied
geographical regions might have diminished these effects. We did not
attempt to identify benefit or detriment of any drug treatment on the
natural history of study populations or assess whether diet, genetic, or
environmental factors influenced health and longevity19,49,53 Moreover,
we could not control for possible regional attitudes towards euthanasia
that might have influenced survival. Finally, cardiac status was based
on 1 initial echocardiographic examination at the point of study entry.
Limitations related to these factors have been detailed.17
5 | CONCLUSIONS
Notwithstanding these limitations, our study contributes new epidemio-
logic information about noncardiovascular and all-cause mortality, includ-
ing incidence rates, risk, and survival outcomes in cats that at study entry
were apparently healthy or had pHCM. The most commonly recorded
noncardiovascular causes of death were cancer, followed by CKD, and
then conditions characterized by CWLVDA. Although life spans of AH
and pHCM cats that died from noncardiovascular causes were similar,
pHCM conferred a substantial health burden over-and-above the risk for
noncardiovascular death. All-cause mortality was significantly greater in
pHCMdue to cardiovascular deathwhich was common in this cohort but
rare inAH.
Noncardiovascular death approximately doubled every successive
age quartile in AH and pHCM cats. Moreover, the increment of risk of
noncardiovascular death was highest at 2.5 years compared with 1 year
after study entry and 5 years compared with 2.5 years after study entry,
respectively, approximately doubling at each comparative time point. Fur-
thermore, increment of noncardiovascular risk was approximately 4 times
higher at 5 years than at 1 year after study entry. Comparatively, this
increment was higher than the increment of risk recorded 10 years versus
5 years after study entry. Still, although noncardiovascular mortality
increased with advancing age, it was also notably present in middle-aged
populations, cohorts that are often underemphasized in contemporary
health screening guidelines.
Collectively, these findings add new epidemiologic information
that may assist veterinarians anticipate potential health conditions,
contribute to the future development of health care guidelines, and
aid long-term surveillance and wellness monitoring strategies.
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